Back to results
US 12,553,030 B2Granted
Genetically engineered T cells with PTPN2 knockout have improved functionality and anti-tumor activity
AssigneeCrispr Therapeutics AG
InventorPaul Tetteh
Life of this patent
Estimating the term…
Abstract
A population of genetically engineered T cells, comprising a disrupted protein tyrosine phosphatase non-receptor type 2 (PTPN2) gene and optionally a disrupted TRAC gene, a disrupted β2M gene, and/or a disrupted CD70 gene. Also provided herein are methods for making such genetically engineered T cells and therapeutic uses thereof.
Claims31
A population of genetically engineered T cells, comprising:
- a nucleic acid encoding a chimeric antigen receptor (CAR);
- a disrupted protein tyrosine phosphatase non-receptor type 2 (PTPN2) gene;
- a disrupted T cell receptor alpha chain constant region (TRAC) gene;
- and
- a disrupted beta-2-microglobulin (β2M) gene, wherein the cells exhibit enhanced survival in the presence of natural killer (NK) cells.
2 more elements
Dependencies are inferred from the claim text.